

Influenza A(H3N2) egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2026-2027 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two- way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

27 February 2026 (Last updated 15 July 2026)

Candidate vaccine viruses antigenically like A/Darwin/1454/2025 (egg-derived) - Accession number (GISAID): EPI_ISL_20260622

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from		
A/Darwin/1369/2025	Wild type virus		VIDRL, Australia	VIDRL, Australia		
A/Darwin/1454/2025	Wild type virus		VIDRL, Australia	VIDRL, Australia		
	IVR-283	Classical	Seqirus	VIDRL, Australia		
A/Darwin/1497/2025	Wild type virus		VIDRL, Australia	VIDRL, Australia		
	SAN-050	Classical	Sanofi	Sanofi		
A/Darwin/1499/2025	Wild type virus		VIDRL, Australia	VIDRL, Australia		
	IVR-284	Classical	Seqirus	VIDRL, Australia		
A/Michigan/105/2025	Wild type virus		CDC, US	CDC, USA MHRA, UK		
	IVR-285	Classical	Seqirus	CCDC, China MHRA, UK		
	SAN-049A	Classical	Sanofi	Sanofi		
	X-463	Classical	NYMC	NYMC		
A/Sichuan-Pingshan/323/2025	Wild type virus		CCDC	CCDC, China		
	CNIC-2601	Classical				
A/Shanghai-Huangpu/12925/2025	Wild type virus					
	CNIC-2602	Classical				
	CNIC-2602A	Classical				

Institutes contact details for candidate vaccine virus orders/information:

CCDC: fluchina@ivdc.chinacdc.cn

CDC: cvvrequest@cdc.gov (Subject: CVV request)

MHRA: standards@mhra.gov.uk or enquiries@mhra.gov.uk

NYMC: andrew_fulvini@nymc.edu

¹ For cell-derived candidate vaccine viruses and reference reagents please see <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

² <https://www.who.int/initiatives/who-listed-authority-reg-authorities>

Sanofi: Raymond.Schwartz@sanofi.com

VIDRL: enquiries@influenzacentre.org

WHO CCs and ERLs: http://www.who.int/influenza/gisrs_laboratory/collaborating_centres

Reference antigens (freeze-dried)

Parent virus	Starting materials		Ref Ag Lot number	Unitage	Available from
	Candidate vaccine virus	Egg or cell		(µg HA/ml)	
A/Michigan/105/2025	IVR-285	Egg	26/100	52	MHRA, UK
			26/102	49	
	SAN-049A		H3-Ag-2604*	65	CBER/FDA, USA
			2026AH3A*	81	NIID, Japan
			2026AH3B*	99	

*New reagent(s) shown in blue

Sheep Antisera

Purified HA from		Order Lot number	Available from
Parent virus	Egg or cell		
A/Darwin/1454/2025-like	Egg	AS469	TGA, Australia
		26/108	MHRA, UK
		H3-Ab-2605*	CBER/FDA, USA
		2026AH3-1*	NIID, Japan

*New reagent(s) shown in blue

WHO Essential Regulatory Laboratories (ERLs) contact details for reagent orders and other information:

MHRA: standards@mhra.gov.uk or enquiries@mhra.gov.uk

NIID: flu-vaccine@nih.go.jp

TGA: influenza.reagents@tga.gov.au

For reagents available from **CBER**, email CBERShippingRequests@fda.hhs.gov.

For information of other type and subtype candidate vaccine viruses and potency testing reagents, please go to: (<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>).

For general enquiries, please contact gisrs-whohq@who.int